Table 4 Impact of NMD on COVID-19
From: A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases
Low COVID-19 severity (n = 48) No. (%) | Moderate COVID-19 severity (n = 23) No. (%) | High COVID-19 severity (n = 12) No. (%) | p-value | |
|---|---|---|---|---|
Type of disease | 0.095 | |||
Myopathy | 16 (59.3) | 8 (29.6) | 3 (11.1) | |
Neuropathy | 12 (52.2) | 10 (43.5) | 1 (4.3) | |
Myasthenia | 20 (60.6) | 5 (15.2) | 8 (24.2) | |
Origin of the disease | 0.199 | |||
Acquired | 24 (55.8) | 10 (23.3) | 9 (20.9) | |
Genetic | 23 (59.0) | 13 (33.3) | 3 (7.7) | |
Severity of neuromuscular diseaseƗ | 0.007* | |||
Low | 21 (72.4) | 6 (20.7) | 2 (6.9) | |
Moderate | 22 (61.1) | 8 (22.2) | 6 (16.7) | |
High | 3 (18.8) | 9 (56.2) | 4 (25.0) | |
Mobility | 0.015* | |||
Walk | 40 (70.2) | 12 (21.1) | 5 (8.8) | |
Walk with help | 5 (41.7) | 4 (33.3) | 3 (25.0) | |
Wheelchair | 3 (25.0) | 6 (50.0) | 3 (25.0) | |
Gender | 0.031* | |||
Men | 14 (41.2) | 14 (41.2) | 6 (17.6) | |
Women | 34 (69.4) | 9 (18.4) | 6 (12.2) | |
Age > 65 yrs old | 9 (47.4) | 9 (47.4) | 1 (5.3) | 0.070 |
Respiratory failure | 12 (42.9) | 10 (35.7) | 6 (21.4) | 0.079 |
Heart failure | 8 (50.0) | 6 (37.5) | 2 (12.5) | 0.617 |
Obesity | 2 (25.0) | 4 (50.0) | 2 (25.0) | 0.097 |
Hypertension | 1 (9.1) | 7 (63.6) | 3 (27.3) | 0.001* |
Diabetes | 1 (10.0) | 4 (40.0) | 5 (50.0) | 0.001* |
Corticosteroids‡,§ | 6 (46.2) | 4 (30.8) | 3 (23.1) | 0.670 |
Immunosuppressants other than corticosteroids‡,§ | 8 (50.0) | 4 (25.0) | 4 (25.0) | 0.764 |